home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550090.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
3KB
|
46 lines
Document 0090
DOCN M9550090
TI [Analysis of host defense mechanism against mycobacterial infection and
its application to therapy with biological response modifiers]
DT 9505
AU Kawakami K; First Department of Internal Medicine, Faculty of Medicine,;
University of the Ryukyus, Okinawa, Japan.
SO Kekkaku. 1994 Nov;69(11):719-23. Unique Identifier : AIDSLINE
MED/95139538
AB Recently, tuberculosis have been increasing among the immunocompromised
patients. In patients with acquired immunodeficiency syndrome (AIDS),
multi-drug resistant mycobacteria are often detected, which make the
therapy difficult. In these patients, chemotherapy alone is often
insufficient and some treatment to augment their host defense activity
has been desired. Therefore, to know the host defense mechanism against
mycobacterial infection will be helpful to develop an adjuvant therapy
for intractable tuberculosis. In this study, IFN-gamma mRNA was induced
in murine lungs after mycobacterial infection, and anti-IFN-gamma
monoclonal antibody (mAb) prevented the activation of pulmonary
intraparenchymal macrophages by M. bovis BCG and the elimination of M.
tuberculosis from lungs. In addition, this mAb inhibited the activation
of Mac1+CD4-CD8- T cells bearing alpha beta antigen receptor by BCG,
which were found in murine lungs and might be involved in the host
defense mechanism against mycobacterial infection, and administration of
IFN-gamma significantly increased this population in lungs. Thus,
IFN-gamma was suggested to be a candidate cytokine for the treatment of
intractable tuberculosis. Next, CD4+ T cell-depleted mice were prepared
by injecting anti-CD4 mAb and used as an immunocompromised model. When
infected with M. tuberculosis, the multiplication of the bacilli within
the lungs of such immunocompromised mice was much more enhanced in
comparison with the control mice with intact CD4+ T cells.
Administration of IFN-gamma significantly reduced the number of the
bacilli in lungs. Further, in an in vitro study with human lung
macrophages, IFN-gamma enhanced the killing activity of macrophages
against M. tuberculosis in a dose dependent manner, and suboptimal dose
of 1 alpha, 25-dihydroxyvitamin D3 synergistically augmented the effect
of IFN-gamma.
DE Animal Biological Response Modifiers/*THERAPEUTIC USE English Abstract
Human Interferon Type II/THERAPEUTIC USE Mice Mycobacterium
Infections/*IMMUNOLOGY/THERAPY JOURNAL ARTICLE REVIEW REVIEW,
TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).